Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 5
Submit an article Journal homepage
240
Views
1
CrossRef citations to date
0
Altmetric
Review

Peptides for Cancer Therapy: a drug-development Opportunity and a drug-delivery Challenge

Gene L BidwellDepartment of Neurology University of Mississippi Medical Center2500 North State [email protected]
Pages 609-621 | Published online: 17 May 2012

References

  • Bidwell GL 3rd, Raucher D. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. Expert Opin. Drug Deliv.6(10), 1033–1047 (2009).
  • Raucher D , MoktanS, MassodiI, BidwellGL 3rd. Therapeutic peptides for cancer therapy. Part II – cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin. Drug Deliv.6(10), 1049–1064 (2009).
  • Draeger LJ , MullenGP. Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J. Biol. Chem.269(3), 1785–1793 (1994).
  • Chen IT , AkamatsuM, SmithMLet al. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene 12(3), 595–607 (1996).
  • Ladner RC , SatoAK, GorzelanyJ, De Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov. Today9(12), 525–529 (2004).
  • Li Y , MaoY, RosalRVet al. Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 C-terminal peptide in human pre-malignant and malignant cells. Int. J. Cancer 115(1), 55–64 (2005).
  • Carvalho G , FabreC, BraunTet al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26(16), 2299–2307 (2007).
  • Fahraeus R , LainS, BallKL, LaneDP. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene16(5), 587–596 (1998).
  • Adams PD , SellersWR, SharmaSK, WuAD, NalinCM, KaelinWG Jr. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol.16(12), 6623–6633 (1996).
  • Widakowich C , De Castro G Jr, De Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist12(12), 1443–1455 (2007).
  • Wee S , JaganiZ, XiangKXet al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69(10), 4286–4293 (2009).
  • Smalley KS , HaassNK, BraffordPA, LioniM, FlahertyKT, HerlynM. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther.5(5), 1136–1144 (2006).
  • Talmadge JE . Pharmacodynamic aspects of peptide administration biological response modifiers. Adv. Drug Deliv. Rev.33(3), 241–252 (1998).
  • Lipka E , CrisonJ, AmidonGL. Transmembrane transport of peptide type compounds: prospects for oral delivery. J. Control. Release39(2–3), 121–129 (1996).
  • Gregoriadis G , JainS, PapaioannouI, LaingP. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm.300(1–2), 125–130 (2005).
  • Adler V , PincusMR, Brandt-RaufPW, RonaiZ. Complexes of p21RAS with JUN N-terminal kinase and JUN proteins. Proc. Natl Acad. Sci. USA92(23), 10585–10589 (1995).
  • Chie L , ChenJM, FriedmanFKet al. Identification of the site of inhibition of oncogenic ras-p21-induced signal transduction by a peptide from a ras effector domain. J. Protein Chem. 18(8), 881–884 (1999).
  • Chie L , ChenJM, FriedmanFKet al. Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the guanine-nucleotide exchange protein, SOS, identified from molecular dynamics calculations. Selective inhibition of oncogenic ras-p21. J. Protein Chem. 18(8), 875–879 (1999).
  • Chung D , AmarS, GlozmanAet al. Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the ras-binding domain of the raf-p74 protein, identified from molecular dynamics calculations. J. Protein Chem. 16(6), 631–635 (1997).
  • Clark GJ , DruganJK, TerrellRSet al. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function. Proc. Natl Acad. Sci. USA 93(4), 1577–1581 (1996).
  • Kelemen BR , HsiaoK, GoueliSA. Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J. Biol. Chem.277(10), 8741–8748 (2002).
  • Agou F , CourtoisG, ChiaravalliJet al. Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. J. Biol. Chem. 279(52), 54248–54257 (2004).
  • Agou F , TraincardF, VinoloEet al. The trimerization domain of NEMO is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains. J. Biol. Chem. 279(27), 27861–27869 (2004).
  • Lin YZ , YaoSY, VeachRA, TorgersonTR, HawigerJ. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem.270(24), 14255–14258 (1995).
  • May MJ , D‘acquistoF, MadgeLA, GlocknerJ, PoberJS, GhoshS. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science289(5484), 1550–1554 (2000).
  • Takada Y , SinghS, AggarwalBB. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J. Biol. Chem.279(15), 15096–15104 (2004).
  • Yaron A , GonenH, AlkalayIet al. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J. 16(21), 6486–6494 (1997).
  • Bottger A , BottgerV, SparksA, LiuWL, HowardSF, LaneDP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol.7(11), 860–869 (1997).
  • Friedler A , HanssonLO, VeprintsevDBet al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl Acad. Sci. USA 99(2), 937–942 (2002).
  • Hupp TR , SparksA, LaneDP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell83(2), 237–245 (1995).
  • Kanovsky M , RaffoA, DrewLet al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl Acad. Sci. USA 98(22), 12438–12443 (2001).
  • Selivanova G , IotsovaV, OkanIet al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3(6), 632–638 (1997).
  • Selivanova G , RyabchenkoL, JanssonE, IotsovaV, WimanKG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell. Biol.19(5), 3395–3402 (1999).
  • Bidwell GL 3rd, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol. Cancer Ther.4(7), 1076–1085 (2005).
  • Bonfanti M , TavernaS, SalmonaM, D‘IncalciM, BrogginiM. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res.57(8), 1442–1446 (1997).
  • Massodi I , MoktanS, RawatA, BidwellGL 3rd, Raucher D. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int. J. Cancer126(2), 533–544 (2010).
  • Mutoh M , LungFD, LongYQ, RollerPP, SikorskiRS, O‘ConnorPM. A p21(Waf1/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res.59(14), 3480–3488 (1999).
  • Warbrick E , LaneDP, GloverDM, CoxLS. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr. Biol.5(3), 275–282 (1995).
  • Fahraeus R , ParamioJM, BallKL, LainS, LaneDP. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol.6(1), 84–91 (1996).
  • Andrews MJ , McinnesC, KontopidisGet al. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org. Biomol. Chem. 2(19), 2735–2741 (2004).
  • Gondeau C , Gerbal-ChaloinS, BelloP, Aldrian-HerradaG, MorrisMC, DivitaG. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J. Biol. Chem.280(14), 13793–13800 (2005).
  • Adams PD , LiX, SellersWRet al. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol. Cell. Biol. 19(2), 1068–1080 (1999).
  • Kashiwagi H , McdunnJE, GoedegebuurePSet al. TAT-Bim induces extensive apoptosis in cancer cells. Ann. Surg. Oncol. 14(5), 1763–1771 (2007).
  • Polster BM , KinnallyKW, FiskumG. BH3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability. J. Biol. Chem.276(41), 37887–37894 (2001).
  • Sattler M , LiangH, NettesheimDet al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275(5302), 983–986 (1997).
  • Schimmer AD , HedleyDW, ChowSet al. The BH3 domain of BAD fused to the antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 8(7), 725–733 (2001).
  • Chai J , DuC, WuJW, KyinS, WangX, ShiY. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature406(6798), 855–862 (2000).
  • Mai JC , MiZ, KimSH, NgB, RobbinsPD. A proapoptotic peptide for the treatment of solid tumors. Cancer Res.61(21), 7709–7712 (2001).
  • Leuschner C , HanselW. Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des.10(19), 2299–2310 (2004).
  • Michl J , ScharfB, SchmidtAet al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int. J. Cancer 119(7), 1577–1585 (2006).
  • Bidwell GL , PerkinsE, RaucherD. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett.319(2), 136–143 (2012).
  • Hosotani R , MiyamotoY, FujimotoKet al. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin. Cancer Res. 8(4), 1271–1276 (2002).
  • Fulda S , WickW, WellerM, DebatinKM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med.8(8), 808–815 (2002).
  • Chengalvala MV , PelletierJC, KopfGS. GnRH agonists and antagonists in cancer therapy. Curr. Med. Chem. Anti Cancer Agents3(6), 399–410 (2003).
  • Cheer SM , PloskerGL, SimpsonD, WagstaffAJ. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs65(18), 2639–2655 (2005).
  • Perez-Marrero R , TylerRC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin. Pharmacother.5(2), 447–457 (2004).
  • Pescarolo MP , BagnascoL, MalacarneDet al. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. FASEB J. 15(1), 31–33 (2001).
  • Walensky LD , KungAL, EscherIet al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305(5689), 1466–1470 (2004).
  • Patch JA , BarronAE. Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers. Curr. Opin. Chem. Biol.6(6), 872–877 (2002).
  • Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev.63(3), 131–135 (2011).
  • Greish K . Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target.15(7–8), 457–464 (2007).
  • Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme. Regul.41, 189–207 (2001).
  • Torchilin VP , LukyanovAN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today8(6), 259–266 (2003).
  • Sato AK , ViswanathanM, KentRB, WoodCR. Therapeutic peptides: technological advances driving peptides into development. Curr. Opin. Biotechnol.17(6), 638–642 (2006).
  • Rosen O , MullerHJ, GokbugetNet al. PEGylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br. J. Haematol. 123(5), 836–841 (2003).
  • Bottomley A , CoensC, SuciuSet al. Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 27(18), 2916–2923 (2009).
  • Eggermont AM , SuciuS, SantinamiMet al. Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633), 117–126 (2008).
  • Van Der Auwera P , PlatzerE, XuZXet al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous PEGylated human G-CSF mutant (Ro 25–8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am. J. Hematol. 66(4), 245–251 (2001).
  • Bowen S , TareN, InoueTet al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 27(3), 425–432 (1999).
  • Nie Y , ZhangX, WangX, ChenJ. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Bioconjug. Chem.17(4), 995–999 (2006).
  • Zhu B , XuHM, ZhaoL, HuangX, ZhangF. Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. J. Biochem.148(3), 341–347 (2010).
  • Zhang G , HanB, LinX, WuX, YanH. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J. Biochem.144(6), 781–788 (2008).
  • J⊘rgensen L , NielsenHM. Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines. Wiley, Chichester, UK (2009).
  • Wang J , ChowD, HeiatiH, ShenWC. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release88(3), 369–380 (2003).
  • Wang J , HogenkampDJ, TranMet al. Reversible lipidization for the oral delivery of leu-enkephalin. J. Drug Target. 14(3), 127–136 (2006).
  • Pardridge WM . Drug and gene delivery to the brain: the vascular route. Neuron36(4), 555–558 (2002).
  • Duncan R . Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm. Sci. Technol. Today2(11), 441–449 (1999).
  • Duvall CL , ConvertineAJ, BenoitDS, HoffmanAS, StaytonPS. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol. Pharm.7(2), 468–476 (2010).
  • Bidwell GL 3rd, Raucher D. Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv. Drug Deliv. Rev.62(15), 1486–1496 (2010).
  • Meyer DE , ChilkotiA. Purification of recombinant proteins by fusion with thermally responsive polypeptides. Nat. Biotechnol.17, 1112–1115 (1999).
  • Meyer DE , ChilkotiA. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules3(2), 357–367 (2002).
  • Urry DW , Luan C-H, Parker TM et al. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J. Am. Chem. Soc.113, 4346–4348 (1991).
  • Dreher MR , LiuW, MichelichCR, DewhirstMW, ChilkotiA. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res.67(9), 4418–4424 (2007).
  • Bidwell GL 3rd, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J. Control. Release135(1), 2–10 (2009).
  • Massodi I , BidwellGL 3rd, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J. Control. Release108(2–3), 396–408 (2005).
  • Massodi I , ThomasE, RaucherD. Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules14(6), 1999–2015 (2009).
  • Bidwell GL 3rd, Whittom AA, Thomas E, Lyons D, Hebert MD, Raucher D. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides31(5), 834–841 (2010).
  • Pan H , SomanNR, SchlesingerPH, LanzaGM, WicklineSA. Cytolytic peptide nanoparticles (‘NanoBees‘) for cancer therapy. Nanomed. Nanobiotechnol.3(3), 318–327 (2011).
  • Tosteson MT , HolmesSJ, RazinM, TostesonDC. Melittin lysis of red cells. J. Membr. Biol.87(1), 35–44 (1985).
  • Bell HS , DufesC, O‘preyJet al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J. Clin. Invest. 117(4), 1008–1018 (2007).
  • Noble CO , KirpotinDB, HayesMEet al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin. Ther. Targets 8(4), 335–353 (2004).
  • Torchilin VP , LevchenkoTS. TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci.4(2), 133–140 (2003).
  • Ducat E , DeprezJ, GilletAet al. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles. Int. J. Pharm. 420(2), 319–332 (2011).
  • Li C , ShenJ, WeiX, XieC, LuW. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy. J. Drug Target.20(3), 264–271 (2012).
  • Kim SK , HuangL. Nanoparticle delivery of a peptide targeting EGFR signaling. J. Control. Release157(2), 279–286 (2012).
  • Pasqualini R , KoivunenE, RuoslahtiE. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol.15(6), 542–546 (1997).
  • Ogris M , WalkerG, BlessingT, KircheisR, WolschekM, WagnerE. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Control. Release91(1–2), 173–181 (2003).
  • Aina OH , SrokaTC, ChenML, LamKS. Therapeutic cancer targeting peptides. Biopolymers66(3), 184–199 (2002).
  • Fay F , ScottCJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy3(3), 381–394 (2011).
  • Giorello L , ClericoL, PescaroloMPet al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 58(16), 3654–3659 (1998).
  • Mae M , LangelU. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol.6(5), 509–514 (2006).
  • Gupta B , LevchenkoTS, TorchilinVP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev.57(4), 637–651 (2005).
  • Rousselle C , ClairP, LefauconnierJM, KaczorekM, ScherrmannJM, TemsamaniJ. New advances in the transport of doxorubicin through the blood–brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol.57(4), 679–686 (2000).
  • Rousselle C , ClairP, SmirnovaMet al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J. Pharmacol. Exp. Ther. 306(1), 371–376 (2003).
  • Schwarze SR , HoA, Vocero-AkbaniA, DowdySF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science285(5433), 1569–1572 (1999).
  • Aguilera TA , OlsonES, TimmersMM, JiangT, TsienRY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr. Biol. (Camb.)1(5–6), 371–381 (2009).
  • Van Den Berg A , DowdySF. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol.22(6), 888–893 (2011).
  • Teesalu T , SugaharaKN, KotamrajuVR, RuoslahtiE. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl Acad. Sci. USA106(38), 16157–16162 (2009).
  • Sugahara KN , TeesaluT, KarmaliPPet al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16(6), 510–520 (2009).
  • Sugahara KN , TeesaluT, KarmaliPPet al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031–1035 (2010).
  • Agemy L , Friedmann-MorvinskiD, KotamrajuVRet al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl Acad. Sci. USA 108(42), 17450–17455 (2011).
  • Olson ES , AguileraTA, JiangTet al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb.)1(5–6), 382–393 (2009).
  • Olson ES , JiangT, AguileraTAet al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl Acad. Sci. USA 107(9), 4311–4316 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.